The efficacy of VUMERITY is based upon bioavailability studies comparing dimethyl fumarate (DMF) to VUMERITY in patients with relapsing forms of MS and healthy subjects1
VUMERITY offers the established efficacy of DMF across Studies 1 and 2
In Study 1 and Study 2 pivotal trials, DMF demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)1
Most common adverse reactions (incidence for DMF ≥10% and ≥2% more than placebo) were, respectively, flushing (40% and 6%), abdominal pain (18% and 10%), diarrhea (14% and 11%), and nausea (12% and 9%)